2010 Advances in Inflammatory Bowel Diseases

2010 Advances in Inflammatory Bowel Diseases | AIBD 2010 2010

The 2010 Advances in Inflammatory Bowel Diseases, Clinical & Research Conference will feature the latest information on IBD treatment and emerging research. The conference is designed to enable clinicians and researchers from all over the world who are working to understand the causes of Crohn's disease and ulcerative colitis to come together to share and gain knowledge. Endorsed by the American College of Gastroenterology (ACG); the American Gastroenterological Association (AGA); and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN), this year's conference will include expanded sessions on and coverage of advances in IBD procedures and surgeries, pediatric IBD, adaptive immunity, and more.

Conference Coverages

AIBD 2010: Strategies for Diagnosing and Managing Microscopic Colitis
AIBD 2010: Strategies for Diagnosing and Managing Microscopic Colitis
The clinical features of microscopic colitis may overlap with those of ulcerative colitis and other bowel conditions.
AIBD 2010: How Do You Explain Risk and Probability to IBD Patients?
Issues of health literacy and numeracy come into play when identifying the best strategies for explaining the risk associated with treatments for IBD.
AIBD 2010: Studies Identify Predictors of IBD Severity, Complications
Several predictors may help clinicians determine which patients with IBD are at risk for more severe disease and potential complications.
AIBD 2010: Do IBD Patients Skip Treatment Due to High Medication Costs?
Although treatment for IBD is expensive, adherence reduces hospitalizations, complications, and other factors that increase the cost of care.
AIBD 2010: Strategies for Managing Loss of Response in IBD Treatment
When IBD patients experience loss of response to therapy, the decision to escalate the dose or switch to other drugs depends on a number of factors.
AIBD 2010: Controversies in IBD: Mucosal Healing vs. Symptom Control
What is the proper balance between mucosal healing and symptom control in treating patients with IBD?
AIBD 2010: What Measure Should Be Used to Assess IBD Outcomes?
Symptoms, not mucosal healing, should be the endpoint used in clinical practice to assess outcomes of patients with inflammatory bowel disease.
AIBD 2010: Promising New Biologics in Development to Treat IBD
Novel biologics in development may provide alternatives to current standards of care in treating patients with refractory inflammatory bowel disease.
AIBD 2010: IBD Treatment Associated with Rare but Serious Complications
Adverse complications associated with IBD treatment may be uncommon, but awareness of these potential side effects is essential for proper management.

Most Popular


$vacMongoViewPlus$ $vAR$